Show simple item record

dc.contributor.authorWatkins, LV
dc.contributor.authorO’Dwyer, M
dc.contributor.authorShankar, R
dc.date.accessioned2022-03-28T08:57:56Z
dc.date.available2022-03-28T08:57:56Z
dc.date.issued2022-05-03
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.urihttp://hdl.handle.net/10026.1/18976
dc.description.abstract

INTRODUCTION: Autism, like other neurodevelopmental disorders (NDDs), has a strong association with epilepsy. There are known common genetic pathways in both autism and epilepsy. There are also specific genetic syndromes associated with both complex epilepsy and the autism phenotype. AREAS COVERED: This review explores the evidence for common genetic etiologies and pathophysiological pathways in relation to both epilepsy and autism. Autism with comorbid epilepsy are associated with a high prevalence of medical and psychiatric comorbidities. This paper discusses how this influences assessment, treatment, and outcomes. The evidence for the treatment of specific seizure types in the context of NDDs is also examined alongside clinical commentary. EXPERT OPINION: Despite the strong association, there is a limited evidence base to support the efficacy and tolerability of anti-seizure medications specifically in autism, with no Level 1 evidence or National Guidance available. Autism and epilepsy should be approached under a NDD model with cautious introduction and titration of anti-seizure medication. Alongside this, there is evidence to support a move toward precision medicine in specific genetic syndromes such as Tuberous Sclerosis Complex and other genetic seizure disorders. The first-line treatments that should be considered for focal seizures include carbamazepine, lamotrigine, and levetiracetam.

dc.format.extent841-851
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoeng
dc.publisherInforma UK Limited
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectComorbidities
dc.subjectgenomic variants
dc.subjectfocal seizures
dc.subjectneurodevelopment
dc.subjectpervasive development
dc.titleA review of the pharmacotherapeutic considerations for managing epilepsy in people with autism
dc.typejournal-article
dc.typeReview
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35341433
plymouth.issue7
plymouth.volume23
plymouth.publisher-urlhttp://dx.doi.org/10.1080/14656566.2022.2055461
plymouth.publication-statusPublished
plymouth.journalExpert Opinion on Pharmacotherapy
dc.identifier.doi10.1080/14656566.2022.2055461
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeEngland
dcterms.dateAccepted2022-03-16
dc.rights.embargodate2023-12-23
dc.identifier.eissn1744-7666
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1080/14656566.2022.2055461
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV